Novo nordisk stops the ocedurenone clarion-ckd trial and recognises impairment loss

BagsvÆrd, denmark, 26 june 2024 – novo nordisk today announced that the clarion-ckd phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around dkk 5.7 billion related to the intangible asset ocedurenone in the second quarter of 2024.
NVO Ratings Summary
NVO Quant Ranking